BackgroundConsidering the pharmacokinetic and pharmacodynamic aspects of different medications, it is plausible that the age of a smoker could affect the half-life of these drugs. The aim of this study was to compare the effectiveness of smoking cessation drugs (nicotine replacement therapy, bupropion, and varenicline) used either in isolation or in combination in adults under and over 60 years of age.MethodsData were collected from 940 Brazilian patients participating in a smoking cessation program. Participants were prescribed smoking cessation medication to be used for at least 12 weeks and were followed for 52 weeks.ResultsCessation rates were significantly different among younger and older participants who were using nicotine replacement therapy (NRT) alone. Being over 60 years of age was significantly associated with increased cessation success among those who used NRT alone (OR 2.34, 95% CI: 1.36 to 4.04, p = 0.002). The effectiveness of varenicline and bupropion were not significantly different according to age groups.ConclusionUsing age as a predictor for tailoring smoking cessation drugs might potentially lead to a more individualized prescription of smoking cessation therapy. These results should be tested in randomized controlled trials.

No abstract

Infarto", metodologia ARIMAX ANEXO B-Modelo estimado para taxa de internações por "AVC", metodologia ARIMAX ANEXO C-Modelo estimado para taxa de mortalidade por "Infarto", metodologia ARIMAX ANEXO D-Modelo estimado para taxa de mortalidade por "AVC", metodologia ARIMAX ANEXO E-Modelo estimado para taxa de internações por "Infarto", metodologia ITSA-ARIMAX ANEXO F-Modelo estimado para taxa de internações por "AVC", metodologia ITSA-ARIMAX ANEXO G-Modelo estimado para taxa de mortalidade por "Infarto", metodologia ITSA-ARIMAX ANEXO H-Modelo estimado para taxa de mortalidade por "AVC", metodologia ITSA-ARIMAX